Sailer Reinhard, Arnold Peter, Erenmemişoğlu Aydin, Martin Wolfgang, Tamur Uygur, Kanzik Ilker, Hincal A Atilla
Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany.
Arzneimittelforschung. 2007;57(4):232-7. doi: 10.1055/s-0031-1296610.
Sultamicillin (CAS 76497-13-7) is a prodrug combination of ampicillin (CAS 69-53-4) and sulbactam (CAS 68373-14-8), with the antibiotic ampicillin and the beta-lactamase inhibitor sulbactam chemically linked as double ester. The present study was performed to investigate the relative bioavailability and to assess the bioequivalence of two different sultamicillin suspensions (Devasid 250 mg/5 ml as test preparation and 375 mg/7.5 ml of the originator product as reference preparation). Twenty-four healthy male volunteers received equal doses of the sultamicillin preparations according to an open, randomised, single-dose, two-period cross-over design with a wash-out phase of 7 days. Blood samples for pharmacokinetic profiling were taken up to 8 h post-dose, and ampicillin and sulbactam plasma concentrations were determined with a validated LC-MS/MS method. Maximum plasma concentrations (C(max)) of 11,267.4 ng/ml (ampicillin, test), 10,864.4 ng/ml (ampicillin, reference), 6,360.6 ng/ml (sulbactam, test and 6,410.7 ng/ml (sulbactam, reference) were achieved. Areas under the plasma concentration-time curve (AUC(0-infinity) of 17,512.9 ng x h/ml (ampicillin, test), 18,388.0 ng x h/ml (ampicillin, reference), 10,971.7 ng ng x h/ml (sulbactam, test) and 11,181.2 ng x h/ml (sulbactam, reference) were calculated. The median t(max) was 0.69 h (ampicillin, test), 0.85 h (ampicillin, reference), 0.72 h (sulbactam, Devasid) and 0.83 h (sulbactam, reference). Plasma elimination half-lives (t(1/2)) of 1.04 h (ampicillin, test), 1.03 h (ampicillin, reference), 1.26 h (sulbactam, Devasid) and 1.00 h (sulbactam, reference) were determined. Both primary target parameters AUC(0-infinity) and C(max) of ampicillin and sulbactam were tested parametrically by analysis of variance (ANOVA) and the 90% confidence intervals were between 84.58%-117.80% (AUC(0-infinity), ampicillin), 92.37%-119.93% (C(max), ampicillin), 85.81%-120.50% (AUC(0-infinity), sulbactam) and 88.41%-117.57% (C(max), sulbactam). Bioequivalence between test and reference preparation was demonstrated since for both parameters AUC and C(max) the 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80%-125%.
舒他西林(CAS 76497-13-7)是氨苄西林(CAS 69-53-4)和舒巴坦(CAS 68373-14-8)的前体药物组合,抗生素氨苄西林和β-内酰胺酶抑制剂舒巴坦通过化学方式连接成双酯。本研究旨在调查两种不同舒他西林混悬液(250 mg/5 ml的Devasid作为试验制剂,375 mg/7.5 ml的原研产品作为参比制剂)的相对生物利用度并评估其生物等效性。24名健康男性志愿者按照开放、随机、单剂量、两周期交叉设计接受等量的舒他西林制剂,洗脱期为7天。给药后长达8小时采集血样进行药代动力学分析,采用经过验证的液相色谱-串联质谱法(LC-MS/MS)测定氨苄西林和舒巴坦的血浆浓度。测得的最大血浆浓度(C(max))分别为:11,267.4 ng/ml(氨苄西林,试验制剂)、10,864.4 ng/ml(氨苄西林,参比制剂)、6,360.6 ng/ml(舒巴坦,试验制剂)和6,410.7 ng/ml(舒巴坦,参比制剂)。计算血浆浓度-时间曲线下面积(AUC(0-∞))分别为:17,512.9 ng·h/ml(氨苄西林,试验制剂)、18,388.0 ng·h/ml(氨苄西林,参比制剂)、10,971.7 ng·h/ml(舒巴坦,试验制剂)和11,181.2 ng·h/ml(舒巴坦,参比制剂)。中位达峰时间(t(max))分别为:0.69小时(氨苄西林,试验制剂)、0.85小时(氨苄西林,参比制剂)、0.72小时(舒巴坦,Devasid)和0.83小时(舒巴坦,参比制剂)。测定的血浆消除半衰期(t(1/2))分别为:1.04小时(氨苄西林,试验制剂)、1.03小时(氨苄西林,参比制剂)、1.26小时(舒巴坦,Devasid)和1.00小时(舒巴坦,参比制剂)。通过方差分析(ANOVA)对氨苄西林和舒巴坦的两个主要目标参数AUC(0-∞)和C(max)进行参数检验,90%置信区间分别为84.58%-117.80%(AUC(0-∞),氨苄西林)、92.37%-119.93%(C(max),氨苄西林)、85.81%-120.50%(AUC(0-∞),舒巴坦)和88.41%-117.57%(C(max),舒巴坦)。由于对于AUC和C(max)这两个参数,对数转换数据的T/R比值的90%置信区间在普遍接受的80%-125%范围内,因此证明了试验制剂和参比制剂之间的生物等效性。